Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Staudt

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Blood|February 1, 2003
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cellsRihab Nasr, Andreas Rosenwald, Marwan E El-Sabban, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials NetworkJeffrey Abrams, Barbara Conley, Margaret Mooney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, et al.
American Journal of Clinical Pathology|December 22, 2010
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy Greiner, et al.
Cancer Research|November 3, 2017
Developing Cancer Informatics Applications and Tools Using the NCI Genomic Data Commons APIShane Wilson, Michael Fitzsimons, Martin Ferguson, et al.
Cell|January 29, 2013
Identification of early replicating fragile sites that contribute to genome instabilityJacqueline H Barlow, Robert B Faryabi, Elsa Callén, et al.
Blood|April 4, 2002
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson, Michael L Grossbard, Stefania Pittaluga, et al.
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
Blood|May 31, 2022
DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOSTyler A Herek, Alyssa Bouska, Waseem Lone, et al.
Cell|December 9, 2014
B cell super-enhancers and regulatory clusters recruit AID tumorigenic activityJason Qian, Qiao Wang, Marei Dose, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Blood|February 1, 2003
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cellsRihab Nasr, Andreas Rosenwald, Marwan E El-Sabban, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials NetworkJeffrey Abrams, Barbara Conley, Margaret Mooney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, et al.
American Journal of Clinical Pathology|December 22, 2010
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy Greiner, et al.
Cancer Research|November 3, 2017
Developing Cancer Informatics Applications and Tools Using the NCI Genomic Data Commons APIShane Wilson, Michael Fitzsimons, Martin Ferguson, et al.
Cell|January 29, 2013
Identification of early replicating fragile sites that contribute to genome instabilityJacqueline H Barlow, Robert B Faryabi, Elsa Callén, et al.
Blood|April 4, 2002
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson, Michael L Grossbard, Stefania Pittaluga, et al.
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
Blood|May 31, 2022
DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOSTyler A Herek, Alyssa Bouska, Waseem Lone, et al.
Cell|December 9, 2014
B cell super-enhancers and regulatory clusters recruit AID tumorigenic activityJason Qian, Qiao Wang, Marei Dose, et al.
Pageof 2